Kyverna Therapeutics Inc Interim Phase 2 Results for MG Conference Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Derek Archila - Wells Fargo - Analyst : Hey, good morning and congrats on the data here great progress. Just few questions for us, I guess first, of the two out of three patients achieving MSC at week 24, obviously very impressive. Is there anything that we can learn from these initial patients, and I guess what's your expectations for the other four for them achieving MSC by week 24 and I have a follow-up.

Question: Derek Archila - Wells Fargo - Analyst : Got it. And then just the second question is just on, were there any patients here that were completely biologic naive and if so, how did they perform relative to the experienced patients? It's just curious because you know you have the ability to enrol those biologic naive patients into the phase three, so I just want to understand the impact of the trial potentially.

Question: Derek Archila - Wells Fargo - Analyst : Got it thank you very much and congrats again.

Question: Derek Archila - Wells Fargo - Analyst : Thanks guys.

Question: Brian Cheng - JP Morgan - Analyst : Hey, guys. Thanks for taking a question and congrats on the update. Warner, can you remind me if the phase two design here has the same washout requirement for standard of care as the phase three? And can you provide a bit more color on that patient, on that one patient that appeared to be in need of other agents? Are you seeing a rebound of their, MG-ADL score? What was the driver there? And then we have a quick follow-up Thank you.

Question: Brian Cheng - JP Morgan - Analyst : Got it. And maybe just one quick one on the SPS front. As we head into the pivotal readout and also the BOA filing, in the, over the next couple of months. Can you also give us some detail on, the pre-launch work that you mentioned in your prepared remarks, what can be done today, between now and BOA filing. Thank you.

Question: Brian Cheng - JP Morgan - Analyst : Great thank you thanks Warner.

Question: Mitchell Kapoor - H.C. Wainwright & Co., LLC - Analyst : Hey team, congrats on the data First Question is that you know the patients in the trial got to an MG-ADL of around three by the three-month mark and just. Bringing that up because we saw the compassionate use patients reach zero by three months and the three compassionate use patients. Can You just talk about the differences that might be contributing whenever we're looking at the compassionate use patients versus the in-trial patients. And then separately, obviously impressive mean MGADL reduction over time you talk about the uniformity or the variability between different patients of the MGADL reductions at Each time point.

Question: Mitchell Kapoor - H.C. Wainwright & Co., LLC - Analyst : That's great thank you. And then last one for me And I think you touched upon it but just Want to confirm How many patients continue to either

Question: Mitchell Kapoor - H.C. Wainwright & Co., LLC - Analyst : Wonderful, thank You, thank you both very much really Appreciate it Thanks Mitchell.

Question: Michael - Morgan Stanley - Analyst : Hi, this is Road on from Mike. Thanks for taking our question. Can you just talk about the baseline MG-ADL scores and QMG scores at baseline and how they compare to the real-world setting, and then secondly, just provide some additional context on the three patients that had neutropenia and how they were treated. Thank.

Question: Thomas Smith - Leerink Partners - Analyst : Hey guys, good morning. Congrats on the data and thanks for taking our questions. Looks like really impressive depth response here in a, really heavily pre-treated patient population. Can you, just clarify the split between ACHR positive patients and the most patients in this data set, and then, can you comment at all on what you're seeing with, respect to the autoantibody levels for these patients and then, I have a follow-up. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. OCTOBER 29, 2025 / 12:00PM, KYTX.OQ - Kyverna Therapeutics Inc Interim Phase 2 Results for MG Conference Call

Question: Thomas Smith - Leerink Partners - Analyst : Got it. That makes sense. Okay. And then, just maybe wanted for Doctor Mini, if I could, can I just ask you to comment on these interim results and how you're thinking about the positioning here for KYV-101 in the treatment paradigm and, maybe just help us understand within your center like how many patients do you think are candidates for KYV-101? How are you thinking about, enrolling patients into a potential phase three study here relative to other mid and late-stage MG studies. Thanks so much.

Question: Sami Corwin - William Blair - Analyst : Congrats on the data and thanks for taking my questions. I was curious how many clinical trial sites you expect to have for the phase three trial, and then I think the prior question was trying to get at this, but Doctor, what percentage of your patients do you think would be good candidates for KYV-101 if this data held up through the phase tree trial? Thank you. Unidentified Company Representative Yeah, it's a great question. I think the challenge is that Currently, these are not available outside clinical trials. So, in general, about 5% to 10% of my patients clinic, would qualify for, clinical trials. One of the challenges with the current clinical trial model that we have with phase three other novel therapies, not KYV-101, is that, they cannot be on other novel therapies, if they want to participate. So just to elaborate, for example. If you want to participate in a new FCR and therapy, then you couldn't be on a compliment therapy or you couldn't be on FCRM therapy, prior, whereas with KYV-101, as long as there is a brief washout period, they should be able to qualify and so in many ways actually it might be easier to recruit, because patients see the degree of the response and we get more comfortable with the degree of response that we're seeing it for patients. And so, but to put an exact number, that's a difficult one to say, but overall, I expect at least. About 10% of the patients will likely qualify whether all of them will, be eager and ready to participate, that's very individual patient selection issue, but I expect that number of patients to qualify for the study criteria.

Question: Sami Corwin - William Blair - Analyst : Great, thank you and congrats again.